NASDAQ$AVIR
Atea Pharmaceuticals Inc · Q3 2022 earnings
Q3 2022 earnings · · Investor relations
Briefing
Atea Pharmaceuticals reported financial results for Q3 2022 and provided a business update.
Atea Pharmaceuticals reported on their progress in advancing clinical candidates, with expectations of pivotal developments in 2023. They anticipate imminent enrollment into the SUNRISE-3 trial for COVID-19, completion of enrollment in the AT-752 challenge study and the first cohort of DEFEND-2, and submission of clinical trial applications for a Hepatitis C study.
- Enrollment of patients into SUNRISE-3 evaluating bemnifosbuvir for COVID-19 is expected imminently.
- Completion of enrollment is anticipated around the end of the year for the AT-752 challenge study and the first cohort of DEFEND-2, with initial data to follow.
- Clinical trial applications for the bemnifosbuvir and ruzasvir combination hepatitis C study are expected to be submitted around year-end, leading to Phase 2 initiation.
- Atea continues to progress its second-generation protease inhibitor discovery program for COVID-19, focused on candidates for combination therapy with bemnifosbuvir.
Headline financials
Revenue & EPS history
Atea · Revenue · Quarterly
$32.8M
Forward guidance
Atea Pharmaceuticals anticipates several key milestones in the near future, including the start of patient enrollment for the SUNRISE-3 trial, completion of enrollment for the AT-752 challenge study and DEFEND-2 trial's first cohort, and submission of clinical trial applications for the combination study of bemnifosbuvir and ruzasvir for Hepatitis C.
Tailwinds
- Expect imminent enrollment of patients into SUNRISE-3 evaluating bemnifosbuvir for COVID-19.
- Anticipate completing enrollment in the AT-752 challenge study around the end of the year.
- Expect to complete enrollment in the first cohort of DEFEND-2 around the end of the year.
- Initial data from AT-752 challenge study and DEFEND-2 trial's first cohort is expected to follow completion of enrollment.
- Expect to submit clinical trial applications for the bemnifosbuvir and ruzasvir combination hepatitis C study around the end of the year, leading to Phase 2 initiation.
Headwinds
- Uncertainty around and costs associated with the clinical development of bemnifosbuvir as a potential treatment for COVID-19.
- Uncertainty around and costs associated with the clinical development of bemnifosbuvir as a potential treatment for HCV.
- Uncertainty around and costs associated with the clinical development of AT-752 for dengue.
- Risks and uncertainties that may cause actual results to differ from forward-looking statements.
- Factors discussed under the caption “Risk Factors” in the Annual Report on Form 10-K could cause actual results to differ materially.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q3 2022
+0.1%
Avg return
Earnings day
+0.6%
Avg return
5 days after
+4.2%
Avg return
30 days after
50%
12 / 24 earnings
Positive
+16.1%
Q1 2021
Best reaction
-16.2%
Q2 2021
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2024 | — | — | — | |
| Q4 2025 | +11.1% | +15.1% | +8.7% | |
| Q3 2025 | -12.1% | -12.9% | -10.0% | |
| Q2 2025 | -2.6% | +1.2% | -2.6% | |
| Q1 2025 | +2.2% | +4.0% | +16.4% | |
| Q4 2024 | -0.3% | +3.3% | -7.0% | |
| Q3 2024 | -2.2% | -7.0% | -17.9% | |
| Q1 2024 | -8.2% | -9.7% | -8.4% | |
| Q4 2023 | -5.5% | -11.4% | -11.4% | |
| Q3 2023 | -10.7% | -14.0% | -10.1% | |
| Q2 2023 | +4.1% | +0.3% | -3.5% | |
| Q1 2023 | -1.2% | -3.0% | +35.8% | |
| Q4 2022 | -8.7% | -0.8% | -8.1% | |
| Q3 2022 | -12.4% | -14.4% | -24.0% | |
| Q2 2022 | -3.5% | -4.3% | -11.7% | |
| Q1 2022 | +12.9% | +36.8% | +52.7% | |
| Q4 2021 | +1.4% | -9.7% | +11.1% | |
| Q3 2021 | +6.5% | +6.5% | -25.3% | |
| Q2 2021 | -16.2% | -12.9% | -13.4% | |
| Q1 2021 | +16.1% | +18.7% | +20.4% | |
| Q2 2020 | +5.3% | -1.4% | -55.0% | |
| Q4 2020 | +5.3% | -1.4% | -55.0% | |
| Q1 2020 | +7.2% | +10.6% | +73.1% | |
| Q4 2019 | +7.2% | +10.6% | +73.1% | |
| Q3 2020 | +7.2% | +10.6% | +73.1% | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — | |
| Q1 2018 | — | — | — | |
| Q4 2017 | — | — | — | |
| Q3 2017 | — | — | — | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — | |
| Q4 2016 | — | — | — | |
| Q3 2016 | — | — | — | |
| Q2 2016 | — | — | — | |
| Q1 2016 | — | — | — | |
| Q4 2015 | — | — | — | |
| Q3 2015 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro